To include your compound in the COVID-19 Resource Center, submit it here.

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday that will take its lead candidate, acne therapy BX001, into the clinic within

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers